Dermatol. praxi. 2020;14(2):85-90 [Med. praxi. 2020;17(1):49-53]

Pitfalls of systemic and local corticosteroid treatment

prof. MUDr. Hana Matějovská Kubešová, CSc., MUDr. Ondřej Výška, MUDr. Jiří Nakládal, Jan Matějovský
Klinika interní, geriatrie a praktického lékařství LF MU a FN Brno

Corticosteroids were first used for therapeutic purposes in patients with rheumatoid arthritis and topically for relief in the case of skin exanthem. With increasing medical knowledge, the indications for their administration have been expanded to include a broad spectrum of clinical conditions. In an acute single-use setting, there is no contraindication to the administration of corticosteroids which can often be life-saving. With long-term treatment, one has to take into consideration the possible risks of adverse side effects resulting from the nature of corticosteroids as agents that provide coping with stress situations, thus increasing blood pressure and blood glucose levels, ensure fluid retention in the body, and mobilize stocks and reserves. In the case of systemic administration, the following have to be expected: destabilization of diabetes or manifestation of prediabetes, decompensation of hypertension, dyslipidaemia, risk of developing gastrointestinal ulcerations due to increased acidity, risk of thromboembolic complications, and negative psychological effects on the patient. There is a significant risk of reactivation of tuberculosis in patients with a positive history. Topical administration of corticosteroids is used, in particular, in pulmonology, allergology, and dermatology, allowing to minimize the occurrence of systemic adverse side effects. However, even this administration is associated with some adverse effects resulting from negative effects on fibrous tissue, i.e. skin and adnexa atrophy, atrophy of subcutaneous fibrous tissue including its function in antigen detection and presentation, and impaired wound healing. During the course of systemic or local corticosteroid treatment, maximum safety of the patient must be ensured through education of both the patient and the carers as well as by a more thorough monitoring of parameters indicating an unfavourable course.

Keywords: steroids, long term administration, diabetes mellitus, tuberculosis, immunosupression.

Published: June 18, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matějovská Kubešová H, Výška O, Nakládal J, Matějovský J. Pitfalls of systemic and local corticosteroid treatment. Dermatol. praxi. 2020;14(2):85-90.
Download citation

References

  1. Burns CM. The History of Cortisone Discovery and Development. Rheum Dis Clin North Am. 2016; 42(1): 1-14. Go to original source... Go to PubMed...
  2. Z historie farmakochemie. Lékařská fakulta MU. Dostupné z: https://is.muni.cz/el/1431/jaro2012/C8790/um/31610507/Z_historie_farmakochemie.pdf
  3. Barnes PJ. Glucocorticoids. Chem Immunol Allergy. 2014; 100: 311-316. Go to original source... Go to PubMed...
  4. He Y, Yi W, Suino-Powell K, et al. Structures and mechanism for the design of highly potent Glucocorticoids. Cell Research 2014; 24: 713-726. Go to original source... Go to PubMed...
  5. Marek J. Léčba kortikoidy. Doporučený postup ČLS JEP 2002.
  6. Bielaková K, Matějovská Kubešová H. Rizika farmakoterapie ve stáří. Praktické lékárenství 2018; 14(1): 8-10. Go to original source...
  7. Oray M, Abu Samra K, Ebrahimiadib N. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4): 457-465. Go to original source... Go to PubMed...
  8. Rasch LA, Bultink IE, van Tuyl LH, Lems WF. Glucocorticoid safety for treating rheumatoid arthritis. Expert Opin Drug Saf. 2015; 14(6): 839-844. Go to original source... Go to PubMed...
  9. Chlíbek R, Karen I, Prymula R, et al. Očkování v ordinaci praktického lékaře. Novelizace 2013. Centrum doporučených postupů pro praktické lékaře.
  10. SPC Prednison. Dostupné z: http://www.sukl.cz/modules/medication/search.php?data%5Bsearch_for%5D=prednison
  11. Mokáň M. Primárna a sekundárna inzulínová rezistencia. Vnitř Lék 2019; 65(4): 264-272. Go to original source... Go to PubMed...
  12. Modlinski R, Fields KB. The Effect of Anabolic Steroids on the Gastrointestinal System, Kidneys, and Adrenal Glands. Current Sports Medicine Reports 2006; 5: 104-109. Go to original source... Go to PubMed...
  13. Kršek M. Systémová léčba glukokortikoidy. Praktický pohled. Vnitřní lékařství 2015; 61(10): 905-913. Go to PubMed...
  14. Žofková I. Léky indukovaná osteoporóza. Vnitř Lék 2013; 59(1): 59-63. Go to PubMed...
  15. Gupta S, Dhillon RJS, Hasni S, et al. Sarcopenia: a Rheumatic Disease? Rheum Dis Clin North Am, 2018; 44(3): 393-404. Go to original source... Go to PubMed...
  16. Topinková E. Sarcopenia as a severe organ failure, its diagnosing and present therapeutic possibilities. Vnitr Lek. Winter 2018; 64(11): 1038-1052. Go to original source... Go to PubMed...
  17. Knytl P, Mohr P. Neuroactive steroids, neurosteroids and their role in Schizophrenia. Psychiatrie 2016; 20(3): 132-138.
  18. Epstein D, Watermayer G, Kirsch R. Review article: The diagnosis and management of Crohn´s Disease in populations with high risk rates of tuberculosis. Aliment Pharmacol Ther 2007; 24: 1373-1388. Go to original source... Go to PubMed...
  19. Rotondo E. Graziosi A, di Stefano V, et al. Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis. BMJ Case Rep. 2018; 11(1). pii: e226687. Go to original source... Go to PubMed...
  20. Nygaard U, Deleuran M, Vestergaard Ch. Emerging Treatment Options in Atopic Dermatitis: Topical Therapies. Dermatology 2017; 233: 333-343. Go to original source... Go to PubMed...
  21. SPC Beloderm. Dostupné z: http://www.sukl.cz/modules/medication/search.php?data%5Bsearch_for%5D=beloderm
  22. Belvisi MG, Hele DJ. Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulmonary Pharmacology & Therapeutics 2003; 16: 321-325. Go to original source... Go to PubMed...
  23. SPC Pulmicort. Dostupné z: http://www.sukl.cz/modules/medication/search.php?data%5Bsearch_for%5D=Pulmicort
  24. SPC Maxitrol. Dostupné z: http://www.sukl.cz/modules/medication/search.php?data%5Bsearch_for%5D=maxitrol
  25. Salice M, Rizzello F, Calabrese C. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2019; 13(6): 557-561. Go to original source... Go to PubMed...
  26. Plaisanu C, Lorgoveanu VC, Lonescu R. Evaluation Of Patients' Awareness Regarding Glucocorticoids Side Effects And Available Prevention Strategies. Romanian Journal Of Rheumatology 2015; 4: 201-206. Go to original source...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.